July 22, 2021 11:01 AM EDT
News Briefing

Al­bireo re­veals $385K price tag for new­ly ap­proved pru­ri­tis drug; Jen­nifer Doud­na's Cari­bou up­sizes IPO

John Carroll

Editor & Founder

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Al­bireo scored a big break­through when it won ap­proval by the FDA and EMA this week for Byl­vay (ode­vix­i­bat), the first drug ap­proved to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s

HHS blasts Boehringer's drug price case, re­veals new de­tails on Jar­diance talks

De­part­ing FDA com­mis­sion­er: 'We're los­ing the bat­tle on mis­in­for­ma­tion'

Broad In­sti­tute pa­per of­fers po­ten­tial new frame­work for treat­ing Hunt­ing­ton’s dis­ease

FDA re­jects Atara's cell ther­a­py for rare trans­plant com­pli­ca­tion, stock craters

Vac­cine patch start­up col­lects an ad­di­tion­al $16M to Se­ries A

A service from the Financial Times